Latest research on Onbrez

Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) under the trade name Onbrez on November 30, 2009, and by the United States Food and Drug Administration (FDA), under the trade name Arcapta Neohaler, on July 1, 2011. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.

Latest findings

Inhalation regimens in the trial were as follows: Spiriva 18 (100% of the patients), Seretide Diskus 50/500 and 50/250 (54% and 4%), Symbicort 9/320 and 4.5/160 (18% and 7%), Inuvair 12/200 and 6/100 (11% and 4%), Pulmicort 400 and 200, Oxis 9, Onbrez 150, and Seretide MDI 25/250 (all 4%). [source, 2016]
We found that a review for one drug in COPD (Arcapta Neohaler) mentioned a MID and reviews for 12 drugs in diabetes (Avandaryl, Symlin, Duetact, Exubera, Januvia, BYETTA, Cycloset, Onglyza, Kombiglyze XR, Victoza, Tradjenta and Bydureon) mentioned a threshold (number of patients achieving the target haemoglobin A1C level) that is linked to patient-centred outcomes. [source, 2015]
Among inhaled bronchodilators, recently-introduced indacaterol (Onbrez) and Glycopyrronium bromide (Seebri) are the preferred choices for COPD treatment because of their powerful bronchodilator effects and a simple once-daily inhalation regimen. [source, 2015]
QVA149 is a fixed-dose combination of two long-acting bronchodilators, indacaterol (QAB149, LABA) and glycopyrronium (NVA237, LAMA), for the once daily maintenance treatment of COPD. [source, 2015]
Then, they answered the mMRC, CAT, and original questionnaires for indacaterol (Onbrez) and the Breezhaler device (it was confirmed that no subjects experienced problems with Breezhaler usage during the visit). [source, 2014]
Because inhaler adherence is very important in the management of COPD,14 questionnaire surveys for indacaterol (Onbrez) and its inhaler device (Breezhaler) were performed. [source, 2014]
The INLIGHT-2 trial was a double-blind study comparing indacaterol (Onbrez Breezhaler®, Novartis) 150 μg daily, Salmeterol (Serevent®, A&H) 50 μg twice daily and placebo [5]; the INHANCE trial compared indacaterol 150 or 300 μg daily with open-label tiotropium (Spiriva®, Boehringer Ingelheim) 18 μg daily [4]. [source, 2013]
A series of systematic searches were carried out, last updated October 2012, using the database PubMed, EMBASE, Cochrane Controlled Trials Register, and Clinical using the following algorithm of MeSH terms: Aclidinium bromide, indacaterol, QAB149, Glycopyrronium bromide, NVA 237, formoterol, tiotropium, long-acting bronchodilators, and COPD, and the searches were repeated with these terms in combination with FEV1, hyperinflation, exercise capacity, dyspnoea, health status, quality of life and exacerbations in order to identify published studies. [source, 2012]
Indacaterol (QAB-149), carmoterol (CHF-4226, TA-2005), GSK-159797, and GSK-642444 are some of these new ultra-LABAs that are still in different phases of clinical development [5, 6]. [source, 2009]